Marex Group’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$951K Buy
6,821
+1,110
+19% +$155K 0.01% 447
2025
Q4
$701K Buy
5,711
+755
+15% +$91.8K ﹤0.01% 475
2025
Q3
$550K Buy
+4,956
New +$563K ﹤0.01% 473
2025
Q2
Sell
-2,086
Closed -$234K 766
2025
Q1
$234K Buy
+2,086
New +$215K ﹤0.01% 540
2024
Q4
Sell
-2,988
Closed -$251K 739
2024
Q3
$251K Sell
2,988
-2,020
-40% -$154K 0.01% 423
2024
Q2
$344K Buy
5,008
+911
+22% +$60.8K 0.01% 384
2024
Q1
$300K Sell
4,097
-318,635
-99% -$24.5M 0.01% 330
2023
Q4
$26.1M Buy
+322,732
New +$25.1M 1.03% 19
2023
Q3
Sell
-35,000
Closed -$2.7M 236
2023
Q2
$2.7M Buy
+35,000
New +$2.79M 0.49% 44
2023
Q1
Sell
-7,100
Closed -$605K 285
2022
Q4
$605K Buy
+7,100
New +$562K 0.09% 151

Other funds holding GILD

Marex Group's GILD Position: Q1 2026 in Review

Marex Group increased its Gilead Sciences (GILD) stake by 19% in Q1 2026, buying an estimated $155K and bringing the position to 6,821 shares worth $951K. The position accounts for 0.01% of the portfolio, ranked #447.

Marex Group first reported a position in GILD in Q4 2022 and has held it in 10 quarters since. The position peaked at $26.1M in Q4 2023. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Marex Group held 6,821 shares of Gilead Sciences worth $951K as of Q1 2026.
  • Marex Group bought 1,110 Gilead Sciences shares in Q1 2026, an estimated $155K.
  • Gilead Sciences made up 0.01% of Marex Group's portfolio in Q1 2026, its #447 holding.
  • Marex Group first reported a position in Gilead Sciences in Q4 2022 and has held it in 10 quarters since.
  • Marex Group's Gilead Sciences position peaked at $26.1M in Q4 2023.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Marex Group's 13F filing for Q1 2026, filed 13 May 2026.